Frederic Guibet France

CTEXDEV develops Augmentative and Alternative Communication (AAC) applications called CommunicoTool, to help non-verbal individuals to communicate.

Industry sectors  E_health


Therapeutics Area  Psychiatry/Psychology

Our innovative solution

 CommunicoTool is an Augmentative and Alternative Communication (AAC) application that provide language communication features including: pictures and pictograms, prerecorded voice, speech synthesis, speech/pain assessment, time management. The application is fully configurable by the end users. Our service is available in French and English in a bilingual version.

Problem  solved

CommunicoTool is an application for tablets suitable for patients with ASD, Stroke, LAS, Cerebral pulsy, with language and communication disorders. Just for ASD, The CDC (Centers for Disease Control and Prevention) estimates about 1 percent of the world population (7 billion) has autism spectrum disorder, and more than 25% of them are non-verbal. 

Market segments

ASD / Stroke / LAS / Cerebral pulsy

Key value proposition

Accessibility / price / Innovation / Configurable

C. Texdev
CEO - Founder 

Mr OLIVE Guillaume France

Urgo Medical The wound healing of the future, now Industry sectors Medtech Therapeutics Area Aesthetics and Dermatology / Advanced Wound Care
Your innovative solution

UrgoTouch is the first preventive laser which significantly improves the post-operative scar aesthetic and functional results.

Which problem are you solving ?

Today, there is no good way to prevent unsightly scars: there should be a solution that would give more control over the scar aesthetic and functional results.

Target market segments

1) Aesthetics surgeons and any surgeon looking to deliver a functional and aesthetic scar after surgery

2) Aesthetics dermatologists for small operations in their office

Key value proposition

1) High level of research, development and clinical performance

2) Restoring patients former quality of life

3) Innnovative breakthrough for a large patient demand

4) Bring Urgo medical grade expertise in skin and healing to the aesthetic market

Urgo Medical
Business Development Manager 

LAURENT HELEWA France

CLEANIS Cleanis invents and manufactures a range of medical grade bags with absorbent pad for the management of body fluids and which are clinically proven to be very effective in the containment of Healthcare-Associated Infections (H.A.I.) such as VRE or the deadly and highly prevalent Clostridium difficile. Cleanis invents and manufactures innovative hygiene medical products for the safe management of body fluids such as sanitary absorbent liners; clinically proven to be very effective in the containment of Hospital Acquired Infections (H.A.I.) Industry sectors Medtech Therapeutics Area Infectious Diseases - Vaccines
Your innovative solution

Carebag is a range of green friendly medical grade bags and liners equipped with a super absorbent pad, designed to replace or cover collection containers such as bedpan ; thus providing a safe solution for the collection, transport and disposal of body fluids whether infectious or not. Made with innovative polymers.

Which problem are you solving ?

The excretas and body fluids management. Carebag has multiple benefits: improvement of hygiene and infection control ; decrease of infection rate ; reduction of Healthcare-Associated Infections (H.A.I.) such as the deadly and highly prevalent C diff. ; substantial cost savings generated by the Reduction of nursing and PPE savings.

Target market segments

Where collection containers such as bedpans or commode pails are used: Hospital (10 to 15% of hospitalization with the support of Infection Preventionnist, especially ICU, Emergency dpt, PACU, post op, cancer treatment center 

Key value proposition

Innovation: Inventor of the product / Leader / Continuous innovation / IP

CLEANIS
President 

Jean Hennequin France

BIOMODEX
CFO 

VINCENT HILLENMEYER France

H4D H4D provides easy and convenient access to a physician through a connected telehealth kiosk, the Consult Station, supported by a best-in-class technology platform. Industry sectors E health Therapeutics Area Cardiology / Vascular Diseases
Dermatology
Infectious Diseases - Vaccines
Nutrition and Weight Loss
Ophthalmology
Otolaryngology (Ear, Nose, Throat)
Pulmonary/Respiratory Diseases
Psychiatry/Psychology
Your innovative solution

The Consult Station

Which problem are you solving ?

Access to care is an increasing challenge throughout the world at a time when chronic diseases, an ageing population and increasing costs challenge current medical organizations. H4D

Target market segments

Corporations, hospitals, retirement communities, rural and remote areas.

Key value proposition

1) Quality and certification for professional medical use, 2) Large functional coverage for primary care uses, 3) Convenient and easy access to a physician, 4) Cost savings.

H4D
COO 

Anne HUMMLER France

Inferential  Biostatistical expertise and services for all types of studies Industry sectors Other: Biostatistics Therapeutics Area Cardiology / Vascular Diseases
CNS-Neurology
Dental and Oral Health
Dermatology
Endocrinology
Gastroenterology / Hepatology
Immunology
Infectious Diseases - Vaccines
Ivd / Diagnostics
Nutrition and Weight Loss
Obstetrics/Gynecology (Women's Health)
Oncology
Ophthalmology
Orthopedics/Orthopedic Surgery
Otolaryngology (Ear, Nose, Throat)
Pulmonary/Respiratory Diseases
Rare Disease
Psychiatry/Psychology
Rheumatology
Your innovative solution

Inferential provides statistical expertise and delivers results and statistical reports for any type of study incl clinical, NIS, health-economics, epidemiology

Which problem are you solving ?

While health authorities are more and more demanding in terms of data quality and study standards, most pharmaceutical companies own less and less skilled statistical resources. Inferential acts as the client's own statistical department or an extension thereof.

Target market segments

1)Pharmaceutical companies 2)Biotechs 3) Device 4) Cosmetics and nutrition 5) Vet

Key value proposition

1) Hign expertise with low overhead costs 2) Broad experience in both US and EMEA regulatory context

Inferential
CEO 

Philippe JAIS France

Innovative non-viral non-integrative gene therapy and DNA vaccination for treatment of severe human diseases based on proprietary set of expression technologies

Eukarys
CEO, CSO 

Mrs Julie JOUGUELET France

  TRIACYS is  a software solutions provider aiming to improve clinical evaluation process and to help collection of data whenever trial subjects are using studied treatments at home.

 Since 2011, TRIACYS offers to its clients and partners a global and collaborative solution for the remote monitoring of subjects when included in home-based clinical trials.

 The offer includes the software customization to collect the data that you want for your trial and the leasing of tactile tablets for each of the subject included in your study. Data collected are accessible in real time on a study dedicated website throughout the study. After study end, TRIACYS provides the sponsor with a comprehensive report on all data collected.

For more details, do not hesitate to contact us.

We are looking forward to discussing with you !

https://www.youtube.com/watch?v=ui3Q6IQsJ14

Mrs Julie JOUGUELET
Triacys
LinkedIn logo US Business Development Manager 

Arnaud Sinan KARABOGA France

THE COMPANY

Finding new uses of safe drugs based on polypharmacology profiling: Armonco® a clinical candidate for lung cancer.

OBJECTIVES FOR THIS EVENT

Harmonic Pharma is looking for a company which would be interested in acquiring the exclusive license of Armonco® in order to perform its clinical development in lung cancer.

TECHNOLOGY AND PRODUCTS

Harmonic Pharma has developed a unique and innovative know-how combining polypharmacology with relevant animal models mimicking human diseases. This expertise has been applied to identify a clinical candidate for lung cancer from existing safe drugs:  Armonco® has been developed to be licensed out for a clinical trial.

KEY ADVANTAGES

New targeted therapy for lung cancer

Armonco® acting in monotherapy and in combination with existing treatments including inhibitor antibodies

Clinical candidate with already well documented safety in man

Cost-effective process and shortening time to market

Consolidated IP including a specific formulation

Ø  Seeking companies interested in discussing common business opportunities in the cancer area

Arnaud Sinan KARABOGA
HARMONIC PHARMA
CSO 

Mrs LAURENCE LABRANQUE France

SOFRIGAM Sofrigam is a cold chain packaging manufacturer for heat-sensitive medicines transportation Industry sectors Cold Chain Packaging Therapeutics Area Infectious Diseases - Vaccines
Oncology
Rare Disease
Your innovative solution

- I-boxe: High-Tech Packaging for very High-value product transportation. A semi-active and smart box protected by two patents and created by a NASA engineer. - Igloo pouche: product for patient transportation drugs. A 2nd version is in the pipeline which would improve the easy and ready to use aspect

Which problem are you solving ?

Sofrigam devises solutions to match the specific demands and requirements of laboratories, biotech, and the need to maintain heat-sensitive products at constant temperatures during transportation. Each year over $1Billion of drugs is fully secured thanks to its insulated solutions. Sofrigam supports companies to achieve their Total Cost of Ownership objectives.

Target market segments

Market segment 1: Biotech Market segment 2: Pharmaceuticals Diagnostics, vaccines and devices Market segment 3: Third-Party Logistics provider Market segment 4: High-value T

Key value proposition

Advantage 1: TCO Mindset Advantage 2: Flexibility Advantage 3: Experience Advantage 4: Time-to-Market

SOFRIGAM
President Executive Assistant